Working… Menu

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00275067
Recruitment Status : Active, not recruiting
First Posted : January 11, 2006
Last Update Posted : February 25, 2020
CTI BioPharma
Information provided by (Responsible Party):
Northwestern University

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving arsenic trioxide and temozolomide together with radiation therapy after surgery may kill any remaining tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of arsenic trioxide and temozolomide when given together with radiation therapy and to see how well they work in treating patients with malignant glioma that has been removed by surgery.

Condition or disease Intervention/treatment Phase
Brain and Central Nervous System Tumors Drug: arsenic trioxide Drug: temozolomide Radiation: radiation therapy Phase 1 Phase 2

Detailed Description:



  • Determine the maximum tolerated dose (MTD) of arsenic trioxide and temozolomide when combined with radiotherapy in patients with resected supratentorial malignant glioma. (Phase I)
  • Determine the toxicity of this regimen in these patients. (Phase I)


  • Determine the 6- and 12-month progression-free survival of patients treated with this regimen once an MTD is reached. (Phase II)
  • Determine the radiographic response for patients treated with the above regimen. (Phase II)
  • Determine the safety of this regimen in these patients. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of arsenic trioxide and temozolomide followed by a phase II study.

  • Phase I: Patients undergo radiotherapy once daily 5 days a week and receive oral temozolomide once daily for approximately 6½ weeks. Patients also receive arsenic trioxide IV over 1-4 hours once daily, 5 days a week in week 1 and then twice a week in weeks 2-7. Beginning within 3-5 weeks after completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 1 year in the absence of disease progression and unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of arsenic trioxide and temozolomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 3 or 2 of 6 patients experience dose-limiting toxicity.

  • Phase II: Patients undergo radiotherapy and receive arsenic trioxide and temozolomide as in phase I at the MTD. Patients then receive temozolomide as in phase I for up to 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 1 year.

PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for the phase I portion of this study. A total of 25 patients will be accrued for the phase II portion of this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of Arsenic Trioxide and Temozolomide in Combination With Radiation Therapy for Patients With Malignant Gliomas
Study Start Date : May 2005
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2021

Arm Intervention/treatment
Experimental: Radiation + temozolomide and arsenic trioxide
Radiation therapy followed by the combination of temozolomide and arsenic trioxide at the maximum tolerated dose determined in phase 1
Drug: arsenic trioxide
Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
Other Names:
  • ATO

Drug: temozolomide
Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
Other Names:
  • TMZ
  • Temodar

Radiation: radiation therapy
All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.

Primary Outcome Measures :
  1. Maximum tolerated dose of arsenic trioxide and temozolomide in combination with radiotherapy [ Time Frame: Toxicity evaluated prior to each treatment cycle ]
    Escalating doses of study drug until dose limiting toxicities are observed.

  2. Collect data on the toxicity of arsenic and temozolomide during radiation therapy [ Time Frame: Toxicity evaluated prior to each treatment cycle ]
    Toxicity of this drug combination during radiation therapy will be assessed.

  3. Assess serum biomarkers and correlate with tumor tissue [ Time Frame: At baseline, during radiation therapy, and prior to each cycle of chemotherapy ]
    Blood will be drawn at baseline, during radiation therapy, and prior to each cycle of chemotherapy to assess serum biomarkers and correlate with tumor tissue.

Secondary Outcome Measures :
  1. Determine progression free survival at 6 and 12 months [ Time Frame: At 6 and 12 months after beginning chemotherapy ]
    Patients will undergo an MRI and neurological evaluation every 6 months while on chemotherapy.

  2. Determine time to disease progression [ Time Frame: At 6 and 12 months after beginning chemotherapy ]
    Disease status will be assessed by MRI and neurological examination every 6 months until disease progression.

  3. To determine overall survival [ Time Frame: Every 6 months while on treatment ]
    Survival status will be evaluated every 6 months while on treatment.

  4. To determine radiographic response to study regimen [ Time Frame: Every 6 months while on treatment ]
    Radiographic response will be assessed by MRI every 6 months while on treatment

  5. To collect safety data during the radiation therapy phase [ Time Frame: Weekly during radiation therapy ]
    EKG's will be done once per week and labs twice per week during radiation therapy phase to evaluate safety data.

  6. To evaluate a potential surrogate marker for outcomes [ Time Frame: At baseline, before and after radiation therapy, and every 2 cycles during chemotherapy ]
    Blood will be drawn to analyze methylation patterns as a surrogate marker for outcomes at baseline, before and after radiation therapy, and every 2 cycles during chemotherapy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed supratentorial malignant glioma of 1 of the following types:

    • Glioblastoma multiforme
    • Gliosarcoma
    • Anaplastic astrocytoma
    • Anaplastic oligodendroglioma
    • Anaplastic mixed gliomas
    • Anaplastic gliomas not otherwise specified
  • Has undergone surgical resection of tumor

    • Patients with biopsy only are eligible
    • Evaluable or measurable disease following resection of recurrent tumor is not mandated for entry into the study
  • No brain metastases


  • Karnofsky performance status 60-100%
  • Life expectancy > 3 months
  • WBC > 3,000/mm^3
  • Absolute neutrophil count > 2,000/mm^3
  • Platelet count > 100,000/mm^3
  • Hemoglobin > 10 g/dL (eligibility level for hemoglobin may be reached by transfusion)
  • Creatinine ≤ 1.5 mg/dL
  • Bilirubin ≤ 2 mg/dL
  • Transaminases ≤ 2 times the upper limit of normal
  • Serum potassium* > 4.0 mEq/dL
  • Serum magnesium* > 1.8 mg/dL NOTE: *If these serum electrolytes are below the specified limits on the baseline laboratory tests, supplemental electrolytes should be administered to bring the serum concentrations to these levels before administering arsenic trioxide
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after completion of study treatment
  • No second-degree heart block
  • QT interval ≤ 460 msec
  • No other malignancy within the past 3 years except curatively treated carcinoma in situ or basal cell carcinoma of the skin
  • Patients who cannot undergo MRI are not eligible for this study
  • No other serious concurrent infection or other medical illness that would jeopardize the ability of the patient to receive the therapy in this protocol with reasonable safety


  • See Disease Characteristics
  • Patients must have recovered from the effects of surgery prior to the start of treatment (10-14 days minimum) and be maintained on a stable corticosteroid regimen for 5 days
  • Concurrent glucocorticoid therapy allowed at the smallest effective dose
  • Patients must be on non-enzyme-inducing anti-convulsants to minimize any drug reaction
  • No prior radiation therapy, chemotherapy, immunotherapy, therapy with biologic agents (including immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy), or hormonal therapy for their brain tumor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00275067

Layout table for location information
United States, Illinois
Hematology-Oncology Associates of Illinois
Chicago, Illinois, United States, 60611-2998
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States, 60611-3013
Edward Cancer Center
Naperville, Illinois, United States, 60540
Sponsors and Collaborators
Northwestern University
CTI BioPharma
Layout table for investigator information
Principal Investigator: Jeffrey Raizer, MD Northwestern University
Layout table for additonal information
Responsible Party: Northwestern University Identifier: NCT00275067    
Other Study ID Numbers: NU 04C1
NU 04C1 ( Other Identifier: Northwestern University )
CDR0000456504 ( Registry Identifier: PDQ )
STU00007792 ( Other Identifier: Northwestern University IRB )
First Posted: January 11, 2006    Key Record Dates
Last Update Posted: February 25, 2020
Last Verified: February 2020
Keywords provided by Northwestern University:
adult anaplastic astrocytoma
adult gliosarcoma
adult anaplastic oligodendroglioma
adult mixed glioma
adult glioblastoma
adult giant cell glioblastoma
recurrent adult brain tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases
Arsenic Trioxide
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents